Innate Pharma (IPHA) Capital Expenditures (2019 - 2025)

Innate Pharma (IPHA) has 7 years of Capital Expenditures data on file, last reported at -$162966.1 in Q4 2025.

• For the quarter ending Q4 2025, Capital Expenditures rose 61.0% year-over-year to -$162966.1; the trailing twelve-month figure through Dec 2025 stood at -$958441.8 (up 15.33% YoY), and the FY2024 full-year result was $417820.8, up 10.64% from the prior year.
• Capital Expenditures for Q4 2025 stood at -$162966.1, up from -$417820.8 in the prior quarter.
• Across five years, Capital Expenditures topped out at -$162966.1 in Q4 2025 and bottomed at -$1.1 million in Q4 2021.
• The 5-year median for Capital Expenditures is -$397737.9 (2023), against an average of -$455086.2.
• The widest annual swing landed in 2022, when Capital Expenditures tumbled 55.06%; it then jumped 61.0% in 2025.
• A 5-year view of Capital Expenditures shows it stood at -$1.1 million in 2021, then surged by 48.64% to -$545832.3 in 2022, then surged by 30.81% to -$377654.9 in 2023, then declined by 10.64% to -$417820.8 in 2024, then surged by 61.0% to -$162966.1 in 2025.
• The last three Capital Expenditures figures came in at -$162966.1 (Q4 2025), -$417820.8 (Q4 2024), and -$377654.9 (Q4 2023), per Business Quant data.

Peer Comparison